{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T20:02:34Z","timestamp":1779739354639,"version":"3.53.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T00:00:00Z","timestamp":1774742400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012781","name":"Merck Sharp and Dohme K.K.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ijantimicag.2026.107790","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T01:04:12Z","timestamp":1774487052000},"page":"107790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Letermovir for CMV prophylaxis after haploidentical HSCT: A prospective study of direct and indirect effects"],"prefix":"10.1016","volume":"67","author":[{"given":"Tong","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengsen","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuejun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3894-0631","authenticated-orcid":false,"given":"Xiaojin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2026.107790_bib0001","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1016\/S1473-3099(25)00069-6","article-title":"Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies","volume":"25","author":"Ljungman","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0002","doi-asserted-by":"crossref","first-page":"136.e1","DOI":"10.1016\/j.jtct.2022.11.011","article-title":"Hematopoietic stem cell transplantation activity in China 2020-2021 during the SARS-CoV-2 pandemic: a report from the Chinese blood and marrow transplantation registry group","volume":"29","author":"Xu","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0003","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/s41375-019-0686-3","article-title":"Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study","volume":"34","author":"Yu","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0004","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41409-019-0499-z","article-title":"The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation","volume":"55","author":"Ciurea","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0005","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0006","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00277-023-05542-6","article-title":"Impact of letermovir prophylaxis in CMV reactivation and disease after allogenic hematopoietic cell transplantation: a real-world, observational study","volume":"103","author":"Brusosa","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0007","doi-asserted-by":"crossref","first-page":"85.e1","DOI":"10.1016\/j.bbmt.2020.10.009","article-title":"Letermovir for prevention of cytomegalovirus reactivation in haploidentical and mismatched adult donor allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis","volume":"27","author":"Lin","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0008","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s12185-022-03348-2","article-title":"Risk factors for late cytomegalovirus infection after completing letermovir prophylaxis","volume":"116","author":"Mori","year":"2022","journal-title":"Int J Hematol"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0009","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.2020009396","article-title":"Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation","volume":"138","author":"Zamora","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0010","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.153175","article-title":"NK and CD8+ T cell phenotypes predict onset and control of CMV DNAemia after kidney transplant","volume":"6","author":"Pickering","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0011","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13904","article-title":"Risk factor analysis for cytomegalovirus reactivation under prophylaxis with letermovir after allogeneic hematopoietic stem cell transplantation","volume":"24","author":"Mizuno","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0012","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41409-023-01920-w","article-title":"Cytomegalovirus breakthrough and resistance during letermovir prophylaxis","volume":"58","author":"Perchetti","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0013","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/cid\/ciae321","article-title":"Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from the transplant associated virus infections forum","volume":"79","author":"Ljungman","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0014","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3324\/haematol.2016.144428","article-title":"Management of Epstein-Barr virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines","volume":"101","author":"Styczynski","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0015","doi-asserted-by":"crossref","first-page":"902.e1-11","DOI":"10.1016\/j.jtct.2024.05.008","article-title":"The role of pre-existing anti-HLA antibodies in severe aplastic anemia patients undergoing allogenic hematopoietic stem cell transplantation","volume":"30","author":"Wei","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0016","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jtct.2021.05.001","article-title":"American Society for Transplantation and Cellular Therapy Series: #3 \u2013 prevention of cytomegalovirus infection and disease after hematopoietic cell transplantation","volume":"27","author":"Hakki","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0017","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/ciab1064","article-title":"Impact of letermovir primary cytomegalovirus prophylaxis on 1-year mortality after allogeneic hematopoietic cell transplantation: a retrospective cohort study","volume":"75","author":"Su","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0018","doi-asserted-by":"crossref","first-page":"ofac687","DOI":"10.1093\/ofid\/ofac687","article-title":"Real-world outcomes associated with letermovir use for cytomegalovirus primary prophylaxis in allogeneic hematopoietic cell transplant recipients: a systematic review and meta-analysis of observational studies","volume":"10","author":"Vyas","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0019","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jtct.2025.06.025","article-title":"American Society for Transplantation and Cellular Therapy Series #11: updated cytomegalovirus guidelines in hematopoietic cell transplant and cellular therapy recipients","volume":"31","author":"Khawaja","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106220","article-title":"Real-world experience with letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation: a multi-centre observational study","volume":"89","author":"P\u00fctz","year":"2024","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0021","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1182\/bloodadvances.2021004362","article-title":"Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients","volume":"5","author":"Hill","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0022","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1111\/bjh.19451","article-title":"Letermovir prophylaxis reduced cytomegalovirus reactivation and resistance post umbilical cord blood transplantation","volume":"204","author":"Yan","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0023","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40164-025-00665-0","article-title":"Epstein-Barr virus infection following allogeneic hematopoietic stem cell transplantation in the era of letermovir for cytomegalovirus prophylaxis","volume":"14","author":"Huang","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0024","doi-asserted-by":"crossref","first-page":"211.e1","DOI":"10.1016\/j.jtct.2022.01.008","article-title":"Human cytomegalovirus-specific T-cell reconstitution and late-onset cytomegalovirus infection in hematopoietic stem cell transplantation recipients following letermovir prophylaxis","volume":"28","author":"Gabanti","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0025","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.bbmt.2014.01.018","article-title":"Early cytomegalovirus reactivation leaves a specific and dynamic imprint on the reconstituting T cell compartment long-term after hematopoietic stem cell transplantation","volume":"20","author":"Lugthart","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0026","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s10238-023-01270-3","article-title":"Early T-cell reconstitution predicts risk of EBV reactivation after allogeneic hematopoietic stem cell transplantation","volume":"24","author":"Huang","year":"2024","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0027","doi-asserted-by":"crossref","first-page":"1450.e1","DOI":"10.1016\/j.cmi.2023.07.026","article-title":"Human herpesvirus-6 reactivation and disease after allogeneic haematopoietic cell transplantation in the era of letermovir for cytomegalovirus prophylaxis","volume":"29","author":"Kampouri","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0028","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/ejh.14117","article-title":"Letermovir prophylaxis for cytomegalovirus reactivation in allogeneic hematopoietic cell transplant recipients: single center Canadian data","volume":"112","author":"Pang","year":"2024","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0029","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/j.cmi.2025.08.017","article-title":"The interplay between Epstein-Barr virus and cytomegalovirus reactivation following allogeneic hematopoietic cell transplantation in the era of primary CMV prophylaxis","volume":"31","author":"Shafat","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0030","first-page":"986","article-title":"[Analysis of CMV and EBV infection in healthy populations in China before and after the COVID-19 pandemic]","volume":"45","author":"Zhao","year":"2024","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0031","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jiac.2022.05.019","article-title":"Real-world efficacy of letermovir prophylaxis for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation: a single-center retrospective analysis","volume":"28","author":"Yoshimura","year":"2022","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0032","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/cid\/ciab298","article-title":"Refractory and resistant cytomegalovirus after hematopoietic cell transplant in the letermovir primary prophylaxis era","volume":"73","author":"Sassine","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0033","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13866","article-title":"Clinical \"real-world\" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients","volume":"34","author":"Anderson","year":"2020","journal-title":"Clin Transplant"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0034","article-title":"Immune reconstitution in the aging host: opportunities for mechanism-based therapy in allogeneic hematopoietic cell transplantation","volume":"12","author":"Lin","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0035","doi-asserted-by":"crossref","first-page":"518.e1","DOI":"10.1016\/j.jtct.2021.03.003","article-title":"Cytomegalovirus prophylaxis versus pre-emptive strategy: different CD4+ and CD8+ T cell reconstitution after allogeneic hematopoietic stem cell transplantation","volume":"27","author":"Sperotto","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0036","first-page":"3806","article-title":"Extending duration of letermovir prophylaxis in haploidentical stem cell transplantation","volume":"109","author":"Vittayawacharin","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0037","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/bcp.15990","article-title":"Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: impact on pharmacokinetics and drug-drug interactions","volume":"90","author":"Armani","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0038","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1182\/blood-2016-01-628982","article-title":"T cells for viral infections after allogeneic hematopoietic stem cell transplant","volume":"127","author":"Bollard","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0039","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1182\/bloodadvances.2023012175","article-title":"Late cytomegalovirus disease after hematopoietic cell transplantation: significance of novel transplantation techniques","volume":"8","author":"Sadowska-Klasa","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.ijantimicag.2026.107790_bib0040","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3026(23)00344-7","article-title":"Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Russo","year":"2024","journal-title":"Lancet Haematol"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926000798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926000798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T19:02:41Z","timestamp":1779735761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857926000798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0924857926000798"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107790","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Letermovir for CMV prophylaxis after haploidentical HSCT: A prospective study of direct and indirect effects","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107790","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107790"}}